Advertisement

Volume 133, Issue 11

 

 

March 14, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Discovery of an affimer protein that reduces clot lysis and has therapeutic potential. See the article by Kearney et al.

Identification and targeting of novel CDK9 complexes in acute myeloid leukemia
In a Plenary Paper, the investigators describe a proteomic analysis and demonstrate that the kinase CDK9, typically associated with transcriptional elongation, directly modulates translation through co-opting mTOR cofactors. These data represent a major shift from the current paradigm and reveal a link to leukemia cell growth and therapeutics.


Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications
This paper reports the discovery of a novel Affimer protein that reduces clot lysis in factor VIII–deficient plasma by binding to fragment D of fibrinogen and possibly reducing access to tissue plasminogen activator. Affimer technology impacts hemophilia therapeutics.


A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
The authors report on the outcome of patients with relapsed mantle cell lymphoma treated with ibrutinib and palbociclib, a first-generation CDK4/6 inhibitor.


Intrahepatic fibrin(ogen) deposition drives liver regeneration after partial hepatectomy in mice and humans
This study adds important insights regarding the direct role of fibrin/fibrinogen in liver regeneration after partial hepatectomy.


How I treat refractory chronic graft-versus-host disease
This How I Treat article addresses many details of the therapeutic management of steroid-refractory graft-versus-host disease.


Kaposi sarcoma–associated herpesvirus/human herpesvirus 8–associated lymphoproliferative disorders
This Blood Spotlight on Kaposi sarcoma–associated herpesvirus (KSHV)–associated lymphoproliferative disorders presents advances in the field related to λ restriction of KSHV-associated B cells and the benefits and limitations of rituximab-based therapy.


Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact
This paper presents the largest retrospective analysis of the prognostic significance of karyotypic complexity, assessed by chromosome banding analysis in patients with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.


Maea expressed by macrophages, but not erythroblasts, maintains postnatal murine bone marrow erythroblastic islands
This study clarifies the in vivo role of macrophage-erythroblast attacher (Maea) in terminal erythropoiesis and demonstrates that Maea-expressing macrophages are essential for erythroblastic island formation and functional erythropoiesis.


View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.